 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
The Body Covers: The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Slide Session 66.A: Drug Interactions in HIV Therapy
September 27, 1999 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! One of the most frequent problems encountered by people with HIV infection is erectile dysfunction. This may arise as a result of illness, medication side effects and other factors. For the past year, many patients have found relief from this problem with the use of ViagraTM (sildenafil citrate). A persistent question, however, has been what, if any, interaction there is between sildenafil and anti-HIV medications, especially protease inhibitors (PI). Muirhead and colleagues studies the interaction of sildenafil with both ritonavir and saquinavir. They did this in 28 healthy HIV-negative volunteers. Subjects received 100 mg of silenafil on day 1 and then on days 2 to 8 they got either saquinavir 1200 mg three times per day or a dose escalation of ritonavir from 300 mg twice per day to 500 mg twice per day. Subjects then received either sildenafil or placebo. The design of this study allowed researchers to observe the sildenafil levels in untreated patients, then allowed the PI to achieve steady state and then repeated the sildenafil with the PI on board. This allowed each subject to serve as his own control. Saquinavir significantly increased Cmax, the peak concentration at 24 hours, the area under the curve (AUC), delayed the time of clearance and increased the half-life of the drug compared to placebo. Ritonavir changed the pharmacokinetic parameters of sildenafil to an even greater extent.
Sildenafil had no effect on the pharmacokinetics of either norvir or saquinavir. The incidence of adverse events was no different in the treatment arm and the placebo arm. The most common AEs were headache, facial flushing, dyspepsia and postural hypotension, all described previously. The authors recommend making no change in the dose of Viagra used with saquinavir, but felt that the large changes in AUC, Cmax, Tmax and T1/2 with ritonavir made dose modification important. They recommend:
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Authored by: G. J. Muirhead, et al.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.
|
||||||||||||||||||||||||||||
Email
Glossary
Print-FriendlyThe Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
